The efficacy of switching intravenous to oral brivaracetam following status epilepticus: A real-world, multicenter Sicilian study
Epilepsy & Behavior · 2025-11 · 172 · 110744
DOI: 10.1016/j.yebeh.2025.110744 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Epilepsy & Behavior, 2025-11. Verfasst von C Martellino und 19 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Status Epilepticus, Anticonvulsants, Pyrrolidinones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Messina.
Abstract (Originalsprache)
BACKGROUND: Brivaracetam (BRV) is a third-generation antiseizure medication (ASM) that acts as a high-affinity ligand for synaptic vesicle protein 2A (SV2A), sharing a similar mechanism of action with levetiracetam (LEV). Nevertheless, BRV exhibits higher binding affinity and selectivity for SV2A and a more favorable safety profile. We aim to study the efficacy of switching intravenous to oral BRV following status epilepticus (SE) and cluster seizures. METHODS: We conducted a multicenter, retrospective, observational study performed at seven Sicilian epilepsy centers in the context of real-world clinical practice. Recruited patients received intravenous BRV as a second-line treatment for SE and subsequently switched to oral administration. Outcome measures were responder rate (≥ 50 % seizure reduction), sustained seizure freedom and the occurrence of adverse events. were defined as the occurrence, number, and type of adverse events (AEs). RESULTS: 75 patients were included in the study whereas seven were excluded because of death before six months of follow-up and five were because lost at follow-up. Sixty-two patients (mean age 69.63 ± 12.99) were included in the present analyses. The mean dosage of BRV was 165 mg (SD 50,04) mg/day at 8.7 months. The retention rate of BRV was 93.7 %. At follow-up, 30 (47.6 %) patients showed sustained seizure freedom, in 22 (34.9 %) seizure frequency decreased ≥ 50 % and 10 (16,1%) experienced a clinical worsening. Adverse events (AEs) were observed in two out of 62 participants (3.2 %). We didn't find any correlation between sex, age, dosage of BRV and the sustained seizure freedom or the reduction in the number of seizures ≥ 50 % (p = 0.57; p = 0.26; p = 0.57, respectively). Patients with vascular aetiology had a likelihood of resolution or a reduction ≥ 50 % approximately three times higher (odds ratio 3.13(IC 95 %: 1.01-9.77), p = 0.05) than others. CONCLUSIONS: The switch of BRV from intravenous to oral administration has demonstrated a good effectiveness and safety profile in long-term treatment of epilepsy following a prior SE particularly in patients with vascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
- National Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy.
- Head of the Center for the Diagnosis and Treatment of Epilepsy - Neurology and Stroke Unit-ARNAS Garibaldi, Catania, Italy.
- Complex Operational Unit of Neurology and Stroke Unit - Sant Antonio Abate Hospital, Trapani, Italy; Head of the Epilepsy Outpatient Clinic, LICE Center, Italy.
- Complex Operational Unit of Neurology and Stroke Unit - R. Guzzardi Hospital, Vittoria, ASP Ragusa, Italy.
- Complex Operational Unit of Neurology - Umberto I Hospital, Enna, Italy.
Förderung
- University of Messina
Zitieren
APA
Martellino, C., Salafica, G., Tripepi, G., Vinaccia, A., Atanasio, G., Tilenni, D., Lamanna, F., Pardeo, O., Panebianco, M., Urso, L., Maira, G., Laisa, P., Zappulla, S., Gammino, M., Coco, D. L., Agrò, L., Avarello, R., Zummo, L., Laganà, A., & Labate, A. (2025). The efficacy of switching intravenous to oral brivaracetam following status epilepticus: A real-world, multicenter Sicilian study. Epilepsy & Behavior, 172, 110744. https://doi.org/10.1016/j.yebeh.2025.110744
Vancouver
Martellino C, Salafica G, Tripepi G, Vinaccia A, Atanasio G, Tilenni D, et al. The efficacy of switching intravenous to oral brivaracetam following status epilepticus: A real-world, multicenter Sicilian study. Epilepsy & Behavior. 2025;172:110744. doi:10.1016/j.yebeh.2025.110744
BibTeX
@article{Martellino2025,
author = {Martellino, C and Salafica, G and Tripepi, G and Vinaccia, A and Atanasio, G and Tilenni, Diana and Lamanna, F and Pardeo, O and Panebianco, M and Urso, L and Maira, G and Laisa, P and Zappulla, S and Gammino, M and Coco, D Lo and Agrò, L and Avarello, R and Zummo, L and Laganà, A and Labate, A},
title = {The efficacy of switching intravenous to oral brivaracetam following status epilepticus: A real-world, multicenter Sicilian study},
journal = {Epilepsy & Behavior},
year = {2025},
volume = {172},
pages = {110744},
doi = {10.1016/j.yebeh.2025.110744}
}
EUVIMED